ABSTRACT
Introduction
The * combined use of antiviral agents helps the enhancement of viral inhibition, the reduction of toxicity and the prevention of antiviral resistance. The application of natural and synthetic viral inhibitors in appropriate combinations also offers possibilities in this direction. This paper presents the results from the investigation of the combined virus-inhibitory effects of two synthetic inhibitors (rimantadine hydrochloride and ε-aminocaproic acid) and two inhibitors of natural * Abbreviation: BF -protease inhibitor, produced by Streptomyces sp. 225b; CPE -cytopathogenic effect; ACA -ε-aminocaproic acid; IVY -Infectious virus yield reduction assay; KIU -Kunitz inhibitory units; MDCK-Madin-Darby canine kidney cells; PCpolyphenol extract from Geranium sanguineum L.; Rim -rimantadine hydrochloride; TCID 50 -50% tissue culture infectious doses.
origin (a protease inhibitor, produced by Streptomyces sp. 225b and a plant polyphenol extract).
Materials and Methods
Substances: Fermentation product from Streptomyces sp. 225b (BF): the strain is from the collection of the Department of Microbiology, Sofia University; the cultivation conditions and the partial purification were as in (1) . Polyphenol extract from Geranium sanguineum L. (PC): the plant material and extraction were as in (7) . Rimantadine hydrochloride (Rim) was purchased from Hoffman -La Roche Inc., Nutley, NJ, USA. ε-aminocaproic acid (ACA) was a gift from Prof. V.P. Lozitsky, Odessa, Anti-plague Institute, Ukraine. Cells and Virus: MDCK cells, media for cultivation and influenza virus A/chicken/Germany/34, strain Rostock (H7N1) (A/Rostock) were as described in (1) . Infectious virus yield (IVY) reduction assay. Triplicate monolayers in 24-well plastic plates were inoculated with 2x drugcontaining medium (0.5 ml) and an equal volume of virus suspension (100 TCID 50 /0.1 ml). The monolayers were incubated at 37 ºC for 24 h. Cells and supernatants were pooled after one freeze-thaw cycle, virus titers were determined by endpoint titration (8) and expressed accordingly in 50% tissue culture infectious doses (TCID 50 /ml).
The combined antiviral effect was determined according to Schinazi et 
Results and Discussion
We investigated the combined virus-inhibitory effects of two synthetic inhibitors (rimantadine hydrochloride, Rim and ε-aminocaproic acid, ACA) and two inhibitors of natural origin (a proteinaceous protease inhibitor, produced by Streptomyces sp. 225b, SS 225 and a polyphenol extract from the medicinal plant Geranium sanguineum L., PC) on the reproduction of influenza virus A/Rostock in MDCK cells. The reduction of infectious virus production was used as a measure of viral inhibition. All four substances have demonstrated significant anti-influenza virus effects both in vitro and in vivo (1, 2, 4, 7, 9) .
The cleavage of the hemagglutinin precursor (HA0) of influenza viruses to subunits HA1 and HA2 by trypsin-like proteases of the host must preceede the fusion process; thus cleavage appears essential for viral infectivity (4, 9) . The inhibition of this step by exogenous protease inhibitors may result in inhibition of viral replication. SS 225 was selected among 25
Streptomyces strains as a result of a screening for the production of proteolytic inhibitors with antiviral properties. The preparation, used in the present study, was a precipitated fermentation product, it contained 13 mg/ml protein, its total inhibitory activity was 1000 KIU/ml (Kunitz inhibitory units/ml). SS 225 was subjected to purification by ion exchange chromatography, gel filtration and HPLC analysis; the inhibitor belongs to the group of serine proteinase inhibitors with MW 14 Da. SS 225 selectively inhibited the replication of a range of influenza viruses; the virus-induced CPE, the production of hemagglutinin and infectious virus were all reduced in a dose-dependent manner. SS 225 affected the penetration into susceptible cells and the late stages of viral replication. In addition SS 225 protected mice from mortality in experimental influenza infection (unpublished results).
The anti-influenza virus effect of the plant extract PC in vitro was shown to be specific and selective. Expression of viral glycoproteins on the surface of virus-infected cells, virus-induced CPE, plaqueformation and infectious virus yields were all reduced at non-toxic concentrations of PC. The action was directed against an early stage of infection. Virus-specific protein and RNA synthesis were selectively inhibited (6) . Phytochemical analysis showed that flavonoids, phenolic acids, gallotannins and catechins were present (3).
Rimantadine hydrochloride is a highly effective drug in the prophylactics and treatment of influenza A virus infection. In case of a number of influenza virus strains inhibition occurs at early stage of virus reproduction, preventing virus uncoating. For certain influenza H7 infections inhibition takes place at a later stage during replication and prevents virus release by a specific interaction with M2 protein (2) .
The anti-influenza virus effect of ε-aminocaproic acid, an inhibitor of plasminogen activation, in vitro and in animal models has been intensively studied by Lozitski et al., 1987 (4) .
The combined use of SS 225+Rim in doses, which by themselves do not suppress significantly viral replication, resulted mostly in synergistic increase of inhibition. Only the combinations of BF1+Rim led to additive enhancement of inhibition (Fig. 1,  Table) .
Except for the combination BF1+ACA1 (antagonistic), the simultaneous application of SS 225 and АСА limited viral replication in a synergistic fashion (Fig. 2, Table) . The combinations of SS 225 and PC resulted predominantly in antagonistic virusinhibitory effects. Solely the combination BF1+PC2 was additive and BF2+PC2 -synergistic (Fig. 3, Table) .
Some of the synergistic interactions were confirmed in experimental infection in mice (unpublished results). Further studies are needed to evaluate the mode of the combined synergistic effects.
The results support the findings that the appropriate combined use of antiviral agents is a promising approach for the treatment of influenza virus infection. Our results show also that in order to achieve a synergistic virus-inhibitory effect it is essential to precisely select not only the individual components to be included but their doses in the combinations as well. 
